RecruitingPhase 3NCT05732272
Improving Smoking Abstinence Outcomes in the African American Community Through Extended Treatment
Sponsor
University of Kansas Medical Center
Enrollment
500 participants
Start Date
Feb 28, 2023
Study Type
INTERVENTIONAL
Conditions
Summary
This study will evaluate the efficacy of extended bupropion(6 months) versus standard bupropion treatment (7 weeks) among African American daily smokers.
Eligibility
Min Age: 18 Years
Plain Language Summary
Simplified for easier understanding
This clinical trial is studying a drug called Bupropion for people with smoking cessation. The study is currently recruiting participants at 1 location. People eligible for this study include aged 18 Years and older.
This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.
Interested in this trial?
Get notified about updates and connect with the research team.
Interventions
DRUGBupropion
150 mg once daily for 3 days, then twice daily for the remainder of the treatment phase.
Locations(1)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT05732272
Related Trials
Precision Treatment to Promote Smoking Cessation and Survival in Oncology Patients
NCT071661202 locations
Multi-Site Trial of Tirzepatide for Smoking Cessation
NCT076026994 locations
Modifying Progesterone and Estradiol Levels to Prevent Postpartum Cigarette Smoking Relapse and Reduce Secondhand Smoke Exposure in Infants and Children
NCT047838571 location
Varenicline and Accelerated Transcranial Magnetic Stimulation (TMS) for Quitting Nicotine Use (Pilot Study)
NCT071458661 location
Preliminary Effectiveness of Enhanced Text Message + Incentives
NCT074206211 location